These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38734079)

  • 21. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
    Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis.
    Challa B; Esnakula AK
    Histopathology; 2024 Apr; 84(5):765-775. PubMed ID: 38114289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
    Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
    Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
    Dougan M
    Immunol Rev; 2023 Sep; 318(1):11-21. PubMed ID: 37455375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver biopsy findings in patients on immune checkpoint inhibitors.
    Cohen JV; Dougan M; Zubiri L; Reynolds KL; Sullivan RJ; Misdraji J
    Mod Pathol; 2021 Feb; 34(2):426-437. PubMed ID: 32884128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitor induced colitis: A nationwide population-based study.
    Farha N; Alkhayyat M; Lindsey A; Mansoor E; Saleh MA
    Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101778. PubMed ID: 34332139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy.
    Joo M; Odze RD
    Am J Surg Pathol; 2010 May; 34(5):689-96. PubMed ID: 20410806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis.
    Yokode M; Shiokawa M; Kawakami H; Kuwada T; Nishikawa Y; Muramoto Y; Kitamoto H; Okabe M; Yamazaki H; Okamoto N; Morita T; Ohno K; Nakanishi R; Takimoto I; Yasuda M; Chikugo K; Matsumoto S; Yoshida H; Ota S; Nakamura T; Okada H; Hirano T; Kakiuchi N; Matsumori T; Yamamoto S; Uza N; Ooi M; Kodama Y; Chiba T; Hayashi H; Seno H
    Br J Cancer; 2024 May; 130(9):1552-1560. PubMed ID: 38461170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.
    Grover S; Dougan M; Tyan K; Giobbie-Hurder A; Blum SM; Ishizuka J; Qazi T; Elias R; Vora KB; Ruan AB; Martin-Doyle W; Manos M; Eastman L; Davis M; Gargano M; Haq R; Buchbinder EI; Sullivan RJ; Ott PA; Hodi FS; Rahma OE
    Cancer; 2020 Aug; 126(16):3758-3767. PubMed ID: 32567084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Cheung VTF; Gupta T; Olsson-Brown A; Subramanian S; Sasson SC; Heseltine J; Fryer E; Collantes E; Sacco JJ; Pirmohamed M; Simmons A; Klenerman P; Tuthill M; Protheroe AS; Chitnis M; Fairfax BP; Payne MJ; Middleton MR; Brain O
    Br J Cancer; 2020 Jul; 123(2):207-215. PubMed ID: 32418993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern.
    Papadimitriou JC; Cangro CB; Lustberg A; Khaled A; Nogueira J; Wiland A; Ramos E; Klassen DK; Drachenberg CB
    Int J Surg Pathol; 2003 Oct; 11(4):295-302. PubMed ID: 14615824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
    Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
    Westdorp H; Sweep MWD; Gorris MAJ; Hoentjen F; Boers-Sonderen MJ; van der Post RS; van den Heuvel MM; Piet B; Boleij A; Bloemendal HJ; de Vries IJM
    Front Immunol; 2021; 12():768957. PubMed ID: 34777387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of characteristic subepithelial surface granulomatosis in immune-related adverse event-associated enterocolitis.
    Kubo T; Hirohashi Y; Keira Y; Akimoto M; Ikeda T; Kikuchi N; Iwaki H; Kikuchi T; Obata M; Morita R; Kasai K; Segawa K; Tsukahara T; Kanaseki T; Murata K; Kikuchi Y; Shinkawa T; Hasegawa T; Torigoe T
    Cancer Sci; 2021 Mar; 112(3):1320-1325. PubMed ID: 33459466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
    Cassol CA; Owen D; Kendra K; Braga JR; Frankel WL; Arnold CA
    Histopathology; 2020 Aug; 77(2):240-249. PubMed ID: 32298485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis.
    Mann JE; Lucca L; Austin MR; Merkin RD; Robert ME; Al Bawardy B; Raddassi K; Aizenbud L; Joshi NS; Hafler DA; Abraham C; Herold KC; Kluger HM
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
    Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
    Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.